Insulin Resistance - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Insulin Resistance - Pipeline Review, H2 2016

Insulin Resistance - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Insulin Resistance - Pipeline Review, H2 2016
Published Jul 20, 2016
49 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Insulin Resistance - Pipeline Review, H2 2016, provides an overview of the Insulin Resistance pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
- The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects
- The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Insulin Resistance

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of In

  
Source:
Document ID
GMDHC8267IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Insulin Resistance Overview71
Therapeutics Development82
  Pipeline Products for Insulin Resistance Overview81
  Pipeline Products for Insulin Resistance Comparative Analysis91
Insulin Resistance Therapeutics under Development by Companies101
Insulin Resistance Therapeutics under Investigation by Universities/Institutes111
Insulin Resistance Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Insulin Resistance Products under Development by Companies141
Insulin Resistance Products under Investigation by Universities/Institutes151
Insulin Resistance Companies Involved in Therapeutics Development167
  Atara Biotherapeutics, Inc.161
  AUS Bio Limited171
  F. Hoffmann-La Roche Ltd.181
  Gilead Sciences, Inc.191
  GlaxoSmithKline Plc201
  Hadasit Medical Research Services &Development Ltd211
  Sanofi221
Insulin Resistance Therapeutics Assessment238
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration281
  Assessment by Molecule Type292
Drug Profiles3116
  ATA-842 Drug Profile311
  Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders Drug Profile321
  englerin A Drug Profile331
  FC-98 Drug Profile341
  GS-444217 Drug Profile351
  L-2286 Drug Profile361
  MD-960 Drug Profile371
  MD-961 Drug Profile381
  Peptide for Obesity and Insulin Resistance Drug Profile391
  RG-7992 Drug Profile401
  SAR-088 Drug Profile411
  Small Molecule for Atherosclerosis and Insulin Resistance Drug Profile421
  Small Molecule for Hypertension and Insulin Resistance Drug Profile431
  Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders Drug Profile441
  SYM-401 Drug Profile451
  Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance Drug Profile461
Insulin Resistance Dormant Projects471
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Insulin Resistance - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Insulin-Resistance-Pipeline-Review-H2-2016-2088-16240>
  
APA:
Global Markets Direct - Market Research. (2016). Insulin Resistance - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Insulin-Resistance-Pipeline-Review-H2-2016-2088-16240>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.